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Abstract We have cloned a novel PP2CL isoform from a
human liver cDNA library which codes for a protein homologous
to other mammalian PP2CLs at the N-terminus but with an
extended C-terminus that is unique amongst the PP2Cs. The
protein expressed in E. coli is indistinguishable from human
recombinant PP2CK in its cation dependence and insensitivity to
okadaic acid. Northern blot analysis of PP2CL along with that
of PP2CK shows that human PP2Cs are widely expressed and
are most abundant in heart and skeletal muscle.
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1. Introduction
Protein phosphorylation/dephosphorylation is one of the
main regulatory systems of cellular function. The major pro-
tein serine/threonine phosphatases in eukaryotic cells have
been divided into four groups: PP1, PP2A, PP2B and PP2C
[1]. PP2C is distinguished from the other groups of phospha-
tases by its absolute requirement for Mg2 (or Mn2) and its
insensitivity to the tumour promoter okadaic acid [2].
PP2C is a monomeric, cytosolic enzyme and two highly
conserved isoforms (K and L) have been found in rodents
[3]. The human PP2CK isoform has been characterised [4]
and recently a novel isoform PP2CN has been described [5].
Here we report a novel human PP2CL isoform PP2CLX that
has a high degree of similarity to rodent PP2CL at the N-
terminus but with a unique extended C-terminus.
2. Materials and methods
2.1. Cloning
A 1.2 kb probe encoding the open reading frame of rat PP2CL
(P35815) was generated by PCR and used to screen a UniZap human
liver library (Stratagene). DNA probe was prepared using random
prime labelling (Pharmacia). Filters were hybridised overnight at
55‡C in 50% formamide, 4USSPE, 20UDenhardts and 2 Wg/ml sal-
mon sperm DNA, with a probe concentration of 22 ng/ml. Filters
were washed in 2USSC for 30 min at room temperature, 0.5USSC
for 30 min at room temperature and 0.5USSC for 30 min at 65‡C.
The ¢lters were exposed to ¢lm overnight at 370‡C with intensifying
screens. A single positive clone (LXa) was rescued using R408 helper
phage following the manufacturers instructions. Since this clone was
incomplete, the 5P end of the gene was ampli¢ed from the same library
using a vector sense primer combined with an antisense oligo from the
5P end of the clone described above. A PCR product (LXb) over-
lapped LXa but was also 5P incomplete. The remaining 40 base pairs
of the 5P end were generated by PCR ampli¢cation from a human
liver GT10 library (Clontech) using a vector sense oligo and antisense
oligo based on the sequence of LXa/b.
2.2. Expression and analysis of phosphatase activity
A full length cDNA based on the combined sequence of La/b/c was
generated by ampli¢cation from HepG2 cell cDNA using HiFi poly-
merase (Boehringer Mannheim). The oligos were tagged with a 5P NdeI
site (GGGAATTCCATATGGGTGCATTTTTGGAT) and 3P XhoI
site which also introduced a C-terminal 6 histidine tag to allow puri-
¢cation on a nickel column (CCGCTCGAGTCAGTGGTGGT-
GGTGGTGGTGTATTTTTTCACCACTCAT). The PCR product
was cloned into the TA cloning vector pGEM (Promega) digested
with NdeI/XhoI and cloned into the E. coli expression vector
pET21a (Novagen). Recombinant plasmids transformed into DH5K
cells (Gibco/BRL) were selected by ampicillin resistance and the se-
quence checked for PCR errors. Plasmid DNA from an error free
clone was used to transform BL21(DE3) cells (Novagen). A culture
was grown to an OD550 of 0.6 and induced with 1 mM IPTG for 2 h
at 37‡C along with a colony transformed with pET21a alone. Cells
were harvested by centrifugation and a 1 ml sample was resuspended
in bu¡er (50 mM Tris, 5 mM EDTA, pH 8), sonicated and the super-
natant removed. The insoluble material was resuspended in 1 ml of
the above bu¡er and 50 Wl each of the soluble and insoluble material
were run on an SDS reducing polyacrylamide gel. The gel was Co-
omassie stained to assess protein levels. The remainder of the cell
pellet was puri¢ed on histidine binding resin (Novagen) following
the manufacturers instructions. Puri¢ed protein was reconstituted in
phosphatase assay bu¡er (50 mM EDTA, 0.5 mM DTT, 10 mM
MnCl2) and assayed with para-nitrophenyl phosphate as substrate
as described previously [4]. Km for activity with this substrate was
determined using Enz¢tter analysis.
2.3. Northern analysis
A commercial Northern blot containing human poly(A)+ RNA
from a range of normal human tissues (Clontech) was used for the
analysis. Probes corresponding to the unique C-termini of PP2CLX
and PP2CK were generated by PCR and were prepared by random
prime labelling (Pharmacia). Filters were pre-hybridised at 65‡C for
15 min and hybridised for 2.5 h at 65‡C in rapid hybridisation bu¡er
(Amersham). Filters were washed in 2USSC/0.05% SDS at room
temperature and then exposed to ¢lm overnight with intensifying
screens at 370‡C.
3. Results and discussion
3.1. Cloning and protein analysis
The cDNA sequence of PP2CLX (Fig. 1) was compiled
from three sequences generated from human liver libraries
as described in Section 2 giving an open reading frame of
1.44 kb. A full length cDNA was ampli¢ed from HepG2 cells
using primers based on this composite clone and the sequence
was veri¢ed by sequence analysis. As can be seen from the
comparison of this sequence with other mammalian PP2CLs
(Fig. 2) the protein is similar to other L isoforms up to the
divergence point, glycine 378 (*), but has an extended C-ter-
minal region. This unique region of the sequence does not
share homology with any other known protein as determined
by BLAST analysis. The protein is 55 kDa in size and is
expressed in E. coli as a partially soluble protein which puri-
FEBS 20471 13-7-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 7 0 8 - X
*Corresponding author. Fax: +44 (1625) 583074.
Abbreviations: PCR, polymerase chain reaction; bp, base pair(s); kb,
kilobase(s)
The sequence reported in this paper has been deposited in the EMBL
database (accession no. AJ005801).
FEBS 20471 FEBS Letters 431 (1998) 121^124
¢ed almost to homogeneity on a nickel histidine binding col-
umn (Fig. 3). We found that the puri¢ed recombinant protein
was biochemically indistinguishable from recombinant human
PP2CK when assayed against p-nitrophenyl phosphate (NPP)
as described previously [4]. The Km with NPP as substrate was
3.5 mM in the presence of 10 mM Mn2 and no inhibition
was seen with okadaic acid. No activity was seen in the ab-
sence of Mn2 (results not shown). We recently published a
paper in which the region of PP2CK important for catalytic
activity was de¢ned by deleting the C-terminus of the protein
[4], and found that the C-terminal part of the protein (9 kDa)
was not required for catalytic activity. It is possible that the
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Fig. 1. DNA and protein sequence of PP2CLX.
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di¡erential C-termini of the PP2Cs play a role in substrate
targeting, although other workers have failed to identify pro-
teins interacting with puri¢ed PP2CL from rat liver and
muscle [6]. Since the method used involved protein puri¢ca-
tion it is possible that interacting proteins were dissociated.
The availability of cDNAs for the PP2C isoforms will make it
possible to search for interactions in a more physiological
environment e.g. in a two-hybrid system.
3.2. Northern analysis
PP2CLX and PP2CK had a similar expression pro¢le being
most predominant in skeletal muscle, heart and liver but also
evident in other tissues (Fig. 4). The widespread expression of
PP2C suggests that it may play a role in regulating phospho-
rylation/dephosphorylation in a number of tissues. Identi¢ca-
tion of intracellular substrates for PP2C has been hampered
by the lack of speci¢c inhibitors, leaving the role of this en-
zyme in vivo unclear. However AMPK (AMP-activated pro-
tein kinase) has been identi¢ed as an intracellular target in
hepatocytes using okadaic acid, a phosphatase inhibitor to
which PP2C is insensitive [7]. It is interesting to note that
the tissue distribution of the PP2C isoforms is similar to
that of AMPK being highly expressed in skeletal muscle [8].
However, despite the high level of protein expression, the
activity of AMPK in this tissue is low and this might be
due to the high level of PP2C in this tissue. The identi¢cation
of proteins which interact with the PP2C isoforms and in
particular with their unique C-termini would help to ¢nd sub-
strates of this enzyme and begin to unravel its intracellular
function.
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Fig. 2. Alignment of human PP2CLX, rat PP2CL and mouse PP2CL1 and PP2CL2.
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Fig. 3. SDS page gel analysis of recombinant PP2CL. Lane 1, solu-
ble PP2C; lane 2, insoluble PP2C; lane 3, soluble control; lane 4,
insoluble control; lane 5: nickel column puri¢ed PP2C; lane 6,
nickel column puri¢ed control.
Fig. 4. Northern blots of human PP2CLX (A), PP2CK (B) and L-ac-
tin (C), nucleic acid probes against the following human tissue pol-
y(A)+ RNAs: Lane 1, heart; lane 2, brain; lane 3, placenta; lane 4,
lung; lane 5, liver; lane 6, skeletal muscle; lane 7, kidney; lane 8,
pancreas.
A.E. Marley et al./FEBS Letters 431 (1998) 121^124124
